Related Experiment Video
Updated: Jun 5, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
[Experimental study on inhibition of restenosis by osteopontin oligopeptide antagonist after de-endothelium]
1Hebei Laboratory of Medical Biotechnology, Institute of Basic Medical Science, Hebei Medical University, Shijiazhuang 050017, China.
Aim:
Osteopontin 13-peptide(Gly158-Lys170), containing multi-function domains was used to inhibit the VSMC adhesion, migration. The mechanism of 13-peptide inhibiting neointima formation was investigated.
Methods:
The effect of 13-peptide on VSMC adhesion was tested by adhesion assay. The restenosis model was prepared balloon injury after administration of 13-peptide for 1 h, and then the 13-peptide was given by an intravenous drip for 7 days. The expression changes of OPN, FAK, ILK in vessel wall were detected by immunohistochemistry and Western blot.
Results:
The 13-peptide dose-dependently reduced adhesion of VSMC in OPN matrix, and the infiltration of macrophage in vessel wall also was reduced in the treatment group after balloon injury. The expression of OPN, FAK, ILK was down-regulated following with the inhibition of neointima thickening.
Conclusion:
The OPN 13-peptide can inhibit inflammation and neointima formation by blocking the binding of OPN to it's receptors.
Insights
Osteopontin 13-peptide effectively inhibits vascular smooth muscle cell adhesion and neointima formation. This peptide reduces inflammation and smooth muscle cell proliferation, offering a potential therapeutic strategy for vascular diseases.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Biochemistry
Context:
- Vascular smooth muscle cell (VSMC) adhesion and migration are key processes in neointima formation.
- Osteopontin (OPN) plays a significant role in vascular remodeling and inflammation.
- Developing targeted therapies to inhibit VSMC proliferation is crucial for treating vascular diseases like restenosis.
Purpose:
- To investigate the mechanism by which the Osteopontin 13-peptide (Gly158-Lys170) inhibits VSMC adhesion, migration, and neointima formation.
- To evaluate the therapeutic potential of the OPN 13-peptide in a balloon injury-induced restenosis model.
Summary:
- The Osteopontin 13-peptide demonstrated a dose-dependent reduction in VSMC adhesion to OPN matrix.
- Administration of the 13-peptide decreased macrophage infiltration and neointima thickening in a rat restenosis model.
- The study observed down-regulation of OPN, FAK, and ILK expression in the vessel wall following 13-peptide treatment.
Impact:
- The OPN 13-peptide shows promise as an anti-inflammatory and anti-proliferative agent for vascular diseases.
- Blocking OPN-receptor interactions with the 13-peptide offers a novel therapeutic approach to prevent neointima formation.
- This research contributes to understanding the molecular mechanisms underlying vascular restenosis and identifies a potential drug candidate.
